NORDHEALTH |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.8 NOK | +15.36% |
|
+12.67% | +36.29% |
| Mar. 05 | Transcript : Nordhealth AS, Q4 2023 Earnings Call, Mar 05, 2024 | |
| Mar. 05 | Nordhealth AS Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 320.8 | 169.7 | 174.6 | 226.6 | - |
| Enterprise Value (EV) 1 | 247.8 | 130.4 | 152.4 | 201.9 | 197.4 |
| P/E ratio | -67.8 x | -12 x | -15.7 x | -28.7 x | -143 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 15.8 x | 10.3 x | 4.74 x | 5.04 x | 4.26 x |
| EV / Revenue | 12.2 x | 7.91 x | 4.14 x | 4.49 x | 3.71 x |
| EV / EBITDA | 131 x | -21.8 x | -122 x | 67.8 x | 22.5 x |
| EV / FCF | 113,160,911 x | - | - | - | - |
| FCF Yield | 0% | - | - | - | - |
| Price to Book | 2.8 x | 1.71 x | - | 3.08 x | 3.15 x |
| Nbr of stocks (in thousands) | 80,000 | 80,192 | 79,045 | 79,045 | - |
| Reference price 2 | 4.010 | 2.116 | 2.209 | 2.867 | 2.867 |
| Announcement Date | 3/8/22 | 3/7/23 | 3/5/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 12.68 | 20.3 | 16.48 | 36.82 | 44.94 | 53.23 |
| EBITDA 1 | - | 1.895 | -5.975 | -1.248 | 2.98 | 8.78 |
| EBIT 1 | - | -4.458 | -14.68 | -11.39 | -8.76 | -2.89 |
| Operating Margin | - | -21.96% | -89.03% | -30.92% | -19.49% | -5.43% |
| Earnings before Tax (EBT) 1 | - | -4.646 | -14.06 | -10.81 | -7.97 | -1.66 |
| Net income 1 | 1.928 | -4.731 | -14.16 | -11.13 | -7.97 | -1.66 |
| Net margin | 15.2% | -23.31% | -85.89% | -30.23% | -17.73% | -3.12% |
| EPS 2 | - | -0.0591 | -0.1770 | -0.1408 | -0.1000 | -0.0200 |
| Free Cash Flow | - | 2.19 | - | - | - | - |
| FCF margin | - | 10.79% | - | - | - | - |
| FCF Conversion (EBITDA) | - | 115.57% | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 6/2/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 73 | 39.2 | 22.2 | 24.7 | 29.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | 2.19 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -13.3% | -12.3% | -10.1% | -2.24% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 1.430 | 1.230 | - | 0.9300 | 0.9100 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 3.38 | - | - | - | - |
| Capex / Sales | - | 16.64% | - | - | - | - |
| Announcement Date | 6/2/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.867
EUR
Average target price
2.581
EUR
Spread / Average Target
-9.97%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +36.29% | 242M | |
| +4.36% | 32.47B | |
| +14.14% | 7.45B | |
| +22.93% | 3.89B | |
| -16.29% | 3.15B | |
| -25.96% | 1.28B | |
| -36.14% | 1.09B | |
| -35.42% | 902M | |
| -0.13% | 893M | |
| -24.12% | 857M |
- Stock Market
- Equities
- NORDH Stock
- Financials Nordhealth
